ArticleAngewandte Chemie (International ed. in English)2023
Neutralizing the Impact of the Virulence Factor LecA from Pseudomonas aeruginosa on Human Cells with New Glycomimetic Inhibitors.
Article in Angewandte Chemie (International ed. in English), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 38 citations in OpenAlex.
- Glyco-Nanogels for Modulating Pseudomonas aeruginosa Biofilm.Macromolecular rapid communications · 2026Article
- Disaccharide-Presenting Iron(II) Complexes as Synthetic Mimics of Natural Glycan Epitopes for Lectin Recognition.Inorganic chemistry · 2026Article
- Exploiting Pharmacokinetic/Pharmacodynamic Methods for Optimizing and Accelerating Drug Development of Innovative Anti-Infectives.ChemMedChem · 2026Review
- Heteromultivalent Nanogels as Highly Potent Inhibitors of Pseudomonas Aeruginosa.Angewandte Chemie (International ed. in English) · 2025Article
- The Parkinson's Disease Drug Tolcapone and Analogues are Potent Glycomimetic Lectin Inhibitors of Pseudomonas aeruginosa LecA.Angewandte Chemie (International ed. in English) · 2025Article
- LecB from Pseudomonas aeruginosa modulates Piezo1 currents and localization in a time-dependent manner.Cellular and molecular life sciences : CMLS · 2025Article
- Glyco-engineered multifunctional hydrogel with bacterial fishing hooks for targeted bacterial eradication and enhanced wound healing.Materials today. Bio · 2025Article
- The BacteriumBiomolecules · 2025Article
- A fucose-binding superlectin from Enterobacter cloacae with high Lewis and ABO blood group antigen specificity.The Journal of biological chemistry · 2025Article
- Bispecific Thio-Linked Disaccharides as Inhibitors of Pseudomonas Aeruginosa Lectins LecA (PA-IL) and LecB (PA-IIL): Dual-Targeting Strategy.Chemistry (Weinheim an der Bergstrasse, Germany) · 2025Article
- Article
- Effective, but Safe? Physiologically Based Pharmacokinetic (PBPK)-Modeling-Based Dosing Study of Molnupiravir for Risk Assessment in Pediatric Subpopulations.ACS pharmacology & translational science · 2024Article
- Dual inhibitors ofChemical science · 2024Article
- A Supramolecular Antibiotic Targeting Drug-ResistantACS applied materials & interfaces · 2024Article
- Insights onMicroorganisms · 2024Article
- Photoswitchable glycoligands targetingBeilstein journal of organic chemistry · 2024Article
- Glycomimetics for the inhibition and modulation of lectins.Chemical Society reviews · 2023Review
- Neutralizing the Impact of the Virulence Factor LecA from Pseudomonas aeruginosa on Human Cells with New Glycomimetic Inhibitors.Angewandte Chemie (International ed. in English) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacterial adhesion, biofilm formation and host cell invasion of the ESKAPE pathogen Pseudomonas aeruginosa require the tetravalent lectins LecA and LecB, which are therefore drug targets to fight these infections. Recently, we have reported highly potent divalent galactosides as specific LecA inhibitors. However, they suffered from very low solubility and an intrinsic chemical instability due to two acylhydrazone motifs, which precluded further biological evaluation. Here, we isosterically substituted the acylhydrazones and systematically varied linker identity and length between the two galactosides necessary for LecA binding. The optimized divalent LecA ligands showed improved stability and were up to 1000-fold more soluble. Importantly, these properties now enabled their biological characterization. The lead compound L2 potently inhibited LecA binding to lung epithelial cells, restored wound closure in a scratch assay and reduced the invasiveness of P. aeruginosa into host cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.